ConductScience.org, home

Comparison · NCT01755598-7382db1a

M72AS01 Group vs Control Group: Number of Subjects With Serious Adverse Events (SAEs).

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. M72AS01 Group vs Control Group: Number of Subjects With Serious Adverse Events (SAEs). Trial comparisons, record NCT01755598-7382db1a. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01755598-7382db1a

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.02860.02180.0373wilson
Risk in group 20.03470.02720.0442wilson
Risk difference, group 1 minus group 2-0.00614-0.01780.00544newcombe hybrid score
Risk ratio, group 1 over group 20.8230.5721.19log
Odds ratio, group 1 over group 20.8180.5611.19log
Number needed to treat, for one fewer participant with the outcome on M72AS01 Group than on Control Group163from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: control.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1M72AS01 Group
Subjects, between, and including, 18 and 50 years of age, who received 2 doses of M72/AS01E according to random assignment, one month apart (Day 0 and Day 30) by intramuscular injection in the deltoid region of the arm.
511,786OG000
Group 2Control Group
Subjects, between, and including,18 and 50 years of age, who received 2 doses of Placebo according to random assignment, one month apart (Day 0 and Day 30) by intramuscular injection in the deltoid region of the arm.
621,787OG001

Outcome

Type
SECONDARY
Title
Number of Subjects With Serious Adverse Events (SAEs).
Description
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time frame
From Day 0 up to Year 3 (during the entire study period)
Population
Analysis was performed on the Total Vaccinated cohort which included all vaccinated subjects with at least one dose administered.

Source ClinicalTrials.gov

Trial

Title
Study to Evaluate the Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine in Adults
NCT number
NCT01755598
Phases
PHASE2
Conditions
Tuberculosis, Tuberculosis Vaccines
Interventions
GSK Biologicals' investigational TB vaccine (GSK692342), Placebo
Lead sponsor
GlaxoSmithKline
Results first posted
2019-12-03

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01755598-7382db1a